PSTX News and Press, Poseida Therapeutics Inc. From 02/07/23

Summary Poseida is emerging as a leader in the allogeneic cell therapy field. A deal struck with Swiss Pharma giant Roche last year involved a $110m upfront payment plus as much as $6bn in development and commercial milestone payments. The 2 companies will develop allogeneic cell th...

Summary Poseida Therapeutics, Inc. granted Takeda its worldwide license to gene-therapy technologies that included piggyBac, Cas-Clover, and biodegradable DNA/ RNA nanoparticle deliveries, including treatments for Hemophilia A. Poseida is advancing its broad pipeline with its CAR-T port...

Summary Poseida Therapeutics caught a strong rally last year following its announced collaboration with Roche. Worth an accretive $6Bn to PSTX, there's scope for the company to accelerate its CAR-T pipeline. As speculators on clinical-stage assets, we are buyers of this rally, eyein...

Poseida Therapeutics ( NASDAQ: PSTX ) on Tuesday said its founder Eric Ostertag had resigned as executive chairman and will retire from its board, effective Feb. 3. Shares of the clinical-stage cell and gene therapy company slipped 8.1% to $6.40 after hours. "Ostertag wil...

Poseida Therapeutics Announces Board Change PR Newswire Eric Ostertag , M.D., Ph.D., Founder and current Executive Chairman, to retire from the Board of Directors and remain a consultant to the Company SAN DIEGO , Jan. 31, 2023 /PRNewswire/ -- Poseida...

Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition ...

Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress PR Newswire P-MUC1C-ALLO1 and P-BCMA-ALLO1 were well tolerated, with no dose-limiting toxicities (DLTs), cytokine release syndrome (CRS...

Hot Penny Stocks To Watch This Month Want to find hot penny stocks to buy ? Some may say to “Follow” the money. That strategy typically involves hunting for insider trading activity or big block buys from hedge funds. One thing that can get overlooked is “the money&#x...

Poseida Therapeutics press release ( NASDAQ: PSTX ): Q3 GAAP EPS of $0.92 beats by $1.57 . Revenue of $116.3M beats by $115.47M . For further details see: Poseida Therapeutics GAAP EPS of $0.92 beats by $1.57, revenue of $116.3M beats by $115.47M

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022 PR Newswire Entered into a strategic collaboration with Roche to develop allogeneic CAR-T cell therapies for hematological indications; received $110 million upfront payment a...